Down-regulation of Neuregulin2 (NRG2) following spinal cord injury in C57BL/6 mice: Its implications in therapeutic potential

Document Type : Original Article

Authors

1 Wuxi School of Medicine, Jiangnan University, Wuxi 214122, Jiangsu, P.R. China

2 Wuxi No.2 People’s Hospital (Jiangnan University Medical Center), Wuxi 214002, Jiangsu, P.R. China

3 Center for Neuroscience, Shantou University Medical College, Shantou 515041, Guangdong, P.R. China

10.22038/ijbms.2025.83787.18131

Abstract

Objective(s): This study aims to elucidate the alterations in Neuregulin 2 (NRG2) and its receptor ErbB4 following spinal cord injury (SCI), as well as to investigate the neuroprotective mechanisms of NRG2 in neurons. 
Materials and Methods: Dataset GSE93561 was analyzed to verify the changes of NRG2-ErbB4 signaling pathway in mice following SCI. The levels of Iba-1 and NRG2 were analyzed by immunohistochemistry, and NRG2 and pErbB4 protein levels were detected by western blot. HT22 cells were scratched and treated with NRG2 dosed from 0–5 nM. Cell mobility was measured at the time point of 0, 24, and 48 hr after scratch. Additionally, western blot was used to detect the protein levels of pErbB4 and pAkt1 at 48 hr. 
Results: By analyzing dataset GSE93561, NRG1, NRG2, and NRG3 were found to be decreased to different degrees post-SCI in mice. The results of immunohistochemistry showed that the level of Iba-1 in the injured core area was significantly increased 8 weeks post-SCI. Western blot analysis showed that the protein levels of NRG2 and pErbB4 were decreased significantly post-SCI. NRG2 promoted HT22 cell migration and dose-dependently increased pErbB4 and pAkt1 protein levels at doses ranging from 0-5 nM. 
Conclusion: The NRG2-ErbB4 signaling pathway was inhibited after SCI in mice. NRG2 promotes the healing of HT22 cells after scratch injury, and the mechanism of NRG2 in the treatment of SCI may be ascribed to the activation of PI3K-Akt signaling pathways downstream to NRG2.

Keywords

Main Subjects

References

1. Silva NA, Sousa N, Reis RL, Salgado AJ. From basics to clinical: A comprehensive review on spinal cord injury. Prog Neurobiol 2014; 114: 25-57.
2. Ackery A, Tator C, Krassioukov A. A global perspective on spinal cord injury epidemiology. J Neurotrauma 2004; 21: 1355-1370.
3. Krityakiarana W, Zhao PM, Nguyen K, Gomez-Pinilla F, Kotchabhakdi N, de Vellis J, et al. Erratum to: Proof-of concept that an acute trophic factors intervention after spinal cord injury provides an adequate niche for neuroprotection, recruitment of nestin-expressing progenitors and regeneration. Neurochem Res 2016; 41: 1844.
4. Thuret S, Moon LD, Gage FH. Therapeutic interventions after spinal cord injury. Nat Rev Neurosci 2006; 7: 628-643.
5. Li S, Li J, Chen G, Lin T, Zhang P, Tong K, et al. Exosomes originating from neural stem cells undergoing necroptosis participate in cellular communication by inducing TSC2 upregulation of recipient cells following spinal cord injury. Neural Regen Res 2025; 20: 3273-3286.
6. Beattie MS, Farooqui AA, Bresnahan JC. Review of current evidence for apoptosis after spinal cord injury. J Neurotrauma 2000; 17: 915-925.
7. Sámano C, Nistri A. Mechanism of neuroprotection against experimental spinal cord injury by riluzole or methylprednisolone. Neurochem Res 2019; 44: 200-213.
8. Deng J, Meng F, Zhang K, Gao J, Liu Z, Li M, et al. Emerging roles of microglia depletion in the treatment of spinal cord injury. Cells 2022; 11: 1871-1883.
9. Normanno N, Bianco C, De Luca A, Salomon DS. The role of EGF-related peptides in tumor growth. Front Biosci 2001; 6: D685-707.
10. Falls DL. Neuregulins: Functions, forms, and signaling strategies. Exp Cell Res 2003; 284: 14-30.
11. Kataria H, Alizadeh A, Karimi-Abdolrezaee S. Neuregulin-1/ErbB network: An emerging modulator of nervous system injury and repair. Prog Neurobiol 2019; 180: 101643.
12. Newbern J, Birchmeier C. Nrg1/ErbB signaling networks in Schwann cell development and myelination. Semin Cell Dev Biol 2010; 21: 922-928.
13. Bartus K, Burnside ER, Galino J, James ND, Bennett DLH, Bradbury EJ. ErbB receptor signaling directly controls oligodendrocyte progenitor cell transformation and spontaneous remyelination after spinal cord injury. Glia 2019; 67: 1036-1046.
14. Alizadeh A, Santhosh KT, Kataria H, Gounni AS, Karimi-Abdolrezaee S. Neuregulin-1 elicits a regulatory immune response following traumatic spinal cord injury. J Neuroinflammation 2018; 15: 53-74.
15. Carraway KL, 3rd, Weber JL, Unger MJ, Ledesma J, Yu N, Gassmann M, et al. Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases. Nature 1997; 387: 512-516.
16. Longart M, Liu Y, Karavanova I, Buonanno A. Neuregulin-2 is developmentally regulated and targeted to dendrites of central neurons. J Comp Neurol 2004; 472: 156-172.
17. Bublil EM, Yarden Y. The EGF receptor family: Spearheading a merger of signaling and therapeutics. Curr Opin Cell Biol 2007; 19: 124-134.
18. Nakano N, Kanekiyo K, Nakagawa T, Asahi M, Ide C. NTAK/neuregulin-2 secreted by astrocytes promotes survival and neurite outgrowth of neurons via ErbB3. Neurosci Lett 2016; 622: 88-94.
19. Zhao WJ, Yi SJ, Ou GY, Qiao XY. Neuregulin 2 (NRG2) is expressed in gliomas and promotes migration of human glioma cells. Folia Neuropathol 2021; 59: 189-197.
20. Zhao W, Lin J. [Neuregulin 2 is highly expressed in glioma tissues to regulate glial fibrillary acidic protein expression via Akt signaling]. Nan Fang Yi Ke Da Xue Xue Bao 2021; 41: 1171-1176.
21. Yan L, Shamir A, Skirzewski M, Leiva-Salcedo E, Kwon OB, Karavanova I, et al. Neuregulin-2 ablation results in dopamine dysregulation and severe behavioral phenotypes relevant to psychiatric disorders. Mol Psychiatry 2018; 23: 1233-1243.
22. Pan HC, Shen YQ, Loers G, Jakovcevski I, Schachner M. Tegaserod, a small compound mimetic of polysialic acid, promotes functional recovery after spinal cord injury in mice. Neuroscience 2014; 277: 356-366.
23. Wei Z, Wang Y, Zhao W, Schachner M. Electro-acupuncture modulates l1 adhesion molecule expression after mouse spinal cord injury. Am J Chin Med 2017; 45: 37-52.
24. Xue WK, Zhao WJ, Meng XH, Shen HF, Huang PZ. Spinal cord injury induced Neuregulin 1 signaling changes in mouse prefrontal cortex and hippocampus. Brain Res Bull 2019; 144: 180-186.
25. Sachdeva R, Gao F, Chan CCH, Krassioukov AV. Cognitive function after spinal cord injury: A systematic review. Neurology 2018; 91: 611-621.
26. Ding Z, Dai C, Zhong L, Liu R, Gao W, Zhang H, et al. Neuregulin-1 converts reactive astrocytes toward oligodendrocyte lineage cells via upregulating the PI3K-AKT-mTOR pathway to repair spinal cord injury. Biomed Pharmacother 2021; 134: 111168-111179.
27. De Mello TR, Busfield S, Dunlop SA, Plant GW. Culture conditions affect proliferative responsiveness of olfactory ensheathing glia to neuregulins. Glia 2007; 55: 734-745.
28. Nakano N, Higashiyama S, Ohmoto H, Ishiguro H, Taniguchi N, Wada Y. The N-terminal region of NTAK/neuregulin-2 isoforms has an inhibitory activity on angiogenesis. J Biol Chem 2004; 279: 11465-11470.
29. Pucko E, Ostrowski R. Targeting protein kinases for anti-glioma treatment. Folia Neuropathol 2020; 58: 287-298.
30. Dao J, Zhang W, Liu C, Li Q, Qiao C, Cui C, et al. Targeted ErbB4 receptor activation prevents D-galactose-induced neuronal senescence via inhibiting ferroptosis pathway. Front Pharmacol 2025:16; 1528604-1528617.
31. Li Q, Ma Z, Qin S, Zhao WJ. Virtual screening-based drug development for the treatment of nervous system diseases. Curr Neuropharmacol 2023; 21: 2447-2464.
Iranian Journal of Basic Medical Sciences
Volume 28, Issue 8
August 2025
Pages 1075-1081

Files

Share

How to cite

Statistics